Theresa A. Deisher
Founder
Biotechnology
AVM Biotechnology
United States of America
Biography
Dr. Theresa A. Deisher, PhD is Founder of AVM Biotechnology LLC and also serves as its Chief Executive Officer, President and Chief Scientific Officer. Ms. Deisher served as Vice President of Research and Development of Cellcyte Genetics Corporation. She is an internationally renowned cardiovascular scientist with extensive expertise in the biotechnology industry. Her research programs have encompassed all areas of cardiovascular physiology and disease, including heart failure, myocardial infarction, thrombosis, stroke, diabetes, obesity, hematopoiesis, immune modulation, cardiotoxicity and regenerative medicine. Dr. Deisher was the first scientist to discover and characterize adult cardiac stem cells, for which she holds the patent. Her most recent appointment prior to CellCyte served as Principal Scientist at Amgen, Inc. from July 2002 to September 2006, where she led an interdepartmental team developing antibody therapeutics for the treatment of chronic heart failure, acute myocardial infarction and chemotherapeutic cardiotoxicity. During her tenure at Amgen, her research group pioneered the use of rodent non-invasive imaging techniques. From October 2000 to August 2006, she served as Senior Staff Scientist, Vascular Biology at Immunex Corp. in Seattle, WA leading projects in Anti-Thrombotics and Inflammation and Myocardial Repair which she successfully transferred over to Amgen with the Immunex acquisition. Her research has resulted in numerous patent awards, out-licensing deals and clinical programs. She has authored numerous manuscripts, has 17 issued or pending patent applications and is a frequent lecturer on stem cell research, inflammation and cardiology. Dr. Deisher received her PhD from Stanford University's Department of Molecular and Cellular Physiology and her BA degree from Stanford University's Department of Human Biology, graduating with honors and distinction.
Research Interest
cardiovascular physiology and disease, including heart failure, myocardial infarction, thrombosis, stroke, diabetes, obesity, hematopoiesis, immune modulation, cardiotoxicity and regenerative medicine